Direct Answer • Key Takeaway
Conclusions: We Analyzed Adverse Ocular Events Recorded in the Fda Adverse Event Reporting System and Found That the Use of Ozempic Is Associated with Higher Rates of Diabetic Retinopathy and Adverse Ocular Events Compared to Other Glp-1 Receptor Agonists.